Validating InoCardia's WorkLoop Model To Support Discovery Safety Improvements

当药物/化学品被开发用于治疗特定疾病或用于人类用途时，它们有时会产生副作用，对心脏造成损害。有时，这些危险的副作用只有在药物/化学品被数千人销售和服用/使用后才被认识到。这是对人类健康的重大风险，当危险产品从市场上撤出时，制药业将付出高昂的代价。虽然药物的副作用可以由许多因素引起，但药物对心肌在全身泵血过程中产生的力量的影响是非常令人担忧的。许多治疗癌症的药物都有很高的风险，可以减少心脏收缩的力量，可能导致心力衰竭的发展和增加死亡率。InoCardia最近开发了一种成功的心脏收缩(变力)评估分析(由InnovateUK和NC3R支持)，目前正被制药行业采用，用于在药物开发的后期临床前阶段管理变力风险。我们的目标是验证我们的高度预测性收缩能力评估技术，用于药物开发的早期化学阶段，以及筛选导致收缩能力问题的风险的能力。

When drugs/chemicals are developed to treat a particular disease or for human use purposes they sometimes have side effects that cause damage to the heart. Occasionally these dangerous side effects are only recognised after the drug/chemical has been marketed & taken/used by thousands of people. This is a significant risk to human health & is costly to the pharmaceutical industry when a dangerous product is withdrawn from market. Although side effects of drugs can be caused by many things, one area of great concern is the effects of drugs on the force that heart muscle can produce during its role in pumping blood around the body. Many drugs developed to treat Cancer have a high risk of reducing the force of contraction of the heart, can lead to the development of heart failure & increased mortality. InoCardia has recently developed a successful heart contractility (inotropy) assessment assay (supported by InnovateUK & NC3R) which is now being adopted by the Pharma Industry to manage inotropy risk at the late pre-clinical stage of drug development. We aim to validate our highly predictive contractility assessment technology for use in the early chemistry phases of drug development and the ability to screen out the risk of causing contractility issues.